OncoSec Medical (ONCS) Receives Coverage Optimism Rating of 0.09

News articles about OncoSec Medical (NASDAQ:ONCS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. OncoSec Medical earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 43.2515581770241 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Get OncoSec Medical alerts: OncoSec Medical (ONCS) Given Buy Rating at Dawson James (americanbankingnews.com) OncoSec Presents Update from Triple Negative Breast Cancer Program at 3rd Global Insight Conference on Breast Cancer (finance.yahoo.com) OncoSec appoints Sara M. Bonstein as CFO and COO (seekingalpha.com) Oncosec Medical (ONCS) Appoints Sara M. Bonstein as CFO and COO (streetinsider.com) OncoSec Appoints Sara M. Bonstein as Chief Financial Officer and Chief Operating Officer (finance.yahoo.com)

ONCS stock traded down $0.02 during trading on Thursday, reaching $1.28. The company’s stock had a trading volume of 367,800 shares, compared to its average volume of 916,959. OncoSec Medical has a 1 year low of $0.88 and a 1 year high of $2.95. The firm has a market capitalization of $68.05 million, a PE ratio of -1.21 and a beta of 2.98.

A number of equities research analysts have issued reports on the company. Dawson James reiterated a “buy” rating on shares of OncoSec Medical in a research note on Monday. HC Wainwright set a $4.00 price target on OncoSec Medical and gave the stock a “buy” rating in a research note on Tuesday. Maxim Group set a $5.00 price target on OncoSec Medical and gave the stock a “buy” rating in a research note on Tuesday, May 8th. Finally, ValuEngine upgraded OncoSec Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $4.33.

In other news, CFO Richard B. Slansky sold 84,984 shares of the firm’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $1.39, for a total transaction of $118,127.76. Following the completion of the transaction, the chief financial officer now owns 255,000 shares in the company, valued at $354,450. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Avtar S. Dhillon sold 37,575 shares of the firm’s stock in a transaction dated Thursday, July 5th. The shares were sold at an average price of $1.39, for a total value of $52,229.25. Following the transaction, the director now owns 181,002 shares of the company’s stock, valued at approximately $251,592.78. The disclosure for this sale can be found here. Insiders sold a total of 300,106 shares of company stock valued at $419,658 in the last quarter. 5.50% of the stock is currently owned by company insiders.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Featured Story: Are analyst ratings accurate?